You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華熙生物(688363.SH):2024年度淨利潤1.64億元,同比下降72.27%
格隆匯 02-27 19:10

格隆匯2月27日丨華熙生物(688363.SH)公佈2024年度業績快報,報吿期內,公司實現營業收入537,082.39萬元,比上年同期下降11.60%;實現歸屬於母公司所有者的淨利潤16,431.59萬元,比上年同期下降72.27%;實現歸屬於母公司所有者的扣除非經常性損益的淨利潤10,122.00萬元,比上年同期下降79.36%。

報吿期內,公司原料業務保持穩健增長,主要受益於公司在國際化戰略中推進的本土化運營,在歐洲、日本、美洲等地銷量實現持續增長,進一步鞏固在全球生物活性物市場的領先地位。公司醫療終端業務保持高速增長,旗下醫美品牌潤致推出兩款醫美針劑新品,有望為公司醫美業務帶來進一步增長空間;同時,通過內生及外延的方式,加速推進各項醫美管線,豐富公司產品線。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account